Skip to content
Not yet recruitingPhase 2

Ketamine for Treatment of Alzheimers Disease Related Depression

NCT07943741 · KeTADiD · Vanderbilt University Medical Center

Closed to entry
Status
Not accepting participants
Phase 2
Phase
30
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems. Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary. Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster. This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Feasibility of the Study as Measured by the Number of Participants Completing the Study

    Measured over From enrollment to the end of safety monitoring at 8 weeks

  • Safety, as Measured by the Number of Participants with At Least One Treatment-Emergent Adverse Event

    Measured over From the first medication infusion through study completion at 8 weeks

  • Clinician-Administered Dissociative States Scale (CADSS) Total Score

    Measured over Week 1 Infusion 1, Week 1 Infusion 2, Week 2 Infusion 1, and Week 2 Infusion 2 prior to and 40 and 90 minutes after the start of each infusion.

  • Severity of Suicidal Thoughts with Montgomery-Åsberg Depression Rating Scale (MADRS) Item 10 Score

    Measured over From enrollment to the end of safety monitoring at 8 weeks

  • Change in Severity of Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Measured over Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2

  • Change in Suicidal Behavior as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Measured over Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2

  • Number of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)

    Measured over Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8

  • Severity of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)

    Measured over Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8

  • Acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)

    Measured over Week 4 (approximately 2 weeks after the final medication infusion)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

60 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Age \>= 60 years; 2. Diagnosis for major depressive disorder meeting DSM5 criteria based on clinical assessment by the study clinician 3. MADRS score \>= 18 4. Clinical diagnosis of MCI or mild dementia due to Alzheimer's Disease 5. Quick Dementia Rating System (QDRS) 2-12 6. Montreal Cognitive Assessment (MoCA) \> 14 at screening 7. Positive AD biomarker (CSF p-tau181/Aβ42, tau/Aβ42, Aβ42/40, amyloid PET, Tau PET or clinical plasma assays such (p-tau 217 or 181), consistent with AD criteria 8. Stable antidepressant medication regimen for at least 4 weeks prior to the start of infusions with plans to continue on the same medication and dose during the study 9. Fluent in English 10. Participants must have a study partner who is able to attend study visits and has regular contact with the participant, defined as approximately 5 or more hours per week, distributed across multiple days 11. Currently be in active treatment with a Vanderbilt Behavioral Health (VBH) provider or community mental health provider. Care must remain continuous for the duration of ketamine treatment. Exclusion Criteria: 1. Prior diagnosis of schizophrenia, bipolar disorder, or personality disorder that would interfere with safely participating in the trial 2. Concomitant or past history of psychiatric or neurologic disorder other than those considered to be related to AD (e.g., head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks, hemorrhagic and/or non-hemorrhagic stroke) 3. Regular use of naltrexone or benzodiazepines 4. History of hypersensitivity, allergy, or intolerance of ketamine, midazolam, or clonidine 5. Current use of memantine, unless the participant and their prescribing clinician agree to discontinue for the duration of the trial. Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist, like ketamine, and is indicated for moderate to severe dementia - not for MCI or mild dementia as the participants enrolled in our trial. If applicable, memantine must be stopped for at least 4 weeks prior to the start of infusions, and participants must refrain from memantine use for the duration of the study 6. Uncontrolled hypertension (systolic \> 160mm HG or diastolic pressure \> 90 mm HG) 7. Unstable angina or recent (6 months) cardiovascular event (e.g., myocardial infarction) 8. Clinically significant arrhythmias or other clinically significant abnormalities on ECG at screening (minor abnormalities documented as clinically insignificant by the site PI are allowed) 9. Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of study drug (e.g., moderate and/or severe untreated obstructive sleep apnea, stroke, or other cerebrovascular conditions, acute glaucoma), as per the site PI's judgement 10. Life expectancy of \< 1 year because of terminal illness 11. Alcohol or substance use disorder of moderate severity or greater in the last year 12. Acute grief (\<1 month) 13. Active suicidality or suicide attempt in 3 months prior 14. Electroconvulsive therapy or transcranial magnetic stimulation in 2 months prior to enrollment 15. Current or planned psychotherapy where the potential participant does not want to pause therapy until 2 weeks after the final infusion

Where

1 study site

FacilityCityRegionCountry
Vanderbilt Psychiatric HospitalNashvilleTennesseeUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07943741 on ClinicalTrials.gov →

Last updated in the registry 2026-11-17. Registry records change; this page reflects the data build of 2026-11-17.

Related

Where this trial sits